Cancer immunology, immunotherapy : CII · 2025
Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Xiangqi, Piao Mingjian, Zhou Zixiang, Wang Shanshan, Li Shuofeng, Zhang Nan, Sun Boyu, Liu Kai, Yang Xu, Yang Xiaobo, Shi Xiaohua, Zhu Chengpei, Zhao Haitao
Аннотация
PURPOSE: To evaluate the characteristics and management of primary (PR) and acquired resistance (AR) to immune checkpoint inhibitor (ICI) combination treatment in patients with unresectable hepatocellular carcinoma (uHCC).
EXPERIMENTAL DESIGN: Patients with uHCC who received ICI combination therapy were retrospectively included. Baseline characteristics, pattern of progression, post-resistance management, and prognosis were recorded and analyzed according to resistance type. The primary endpoint was overall survival (OS).
RESULTS: A hundred and eighty-eight out of 262 patients (71.8%) developed resistance, including 35.1% with PR and 36.6% with AR. All AR developed within 2 years. Patients with AR had better general conditions, smaller tumors, fewer vessel invasion and better prognosis (median OS [mOS]: 25.8 vs. 8.63 months) than those with PR. Patients with AR were less likely to have multiple lesions and sites exhibiting progression. Occurrence of new lesions led to a decrease in OS in patients with PR but an increase in those with AR. Patients with either PR or AR receiving post-resistance anti-tumor treatment showed improved OS, but patients with AR had significantly longer OS than those with PR. The combination of subsequent local therapy (mOS 25.6 vs. 10.0 months) and changes in the ICI regimen (mOS 27.5 vs. 13.4 months) led to improved OS among patients with PR.
CONCLUSIONS: AR normally develops within 2 years after the beginning of treatment. Patients with AR have better characteristics in general, less invasive pattens of progression, and better prognosis compared to those with PR. Subsequent local therapy and changes in ICI treatment showed potential to overcome primary resistance.
EXPERIMENTAL DESIGN: Patients with uHCC who received ICI combination therapy were retrospectively included. Baseline characteristics, pattern of progression, post-resistance management, and prognosis were recorded and analyzed according to resistance type. The primary endpoint was overall survival (OS).
RESULTS: A hundred and eighty-eight out of 262 patients (71.8%) developed resistance, including 35.1% with PR and 36.6% with AR. All AR developed within 2 years. Patients with AR had better general conditions, smaller tumors, fewer vessel invasion and better prognosis (median OS [mOS]: 25.8 vs. 8.63 months) than those with PR. Patients with AR were less likely to have multiple lesions and sites exhibiting progression. Occurrence of new lesions led to a decrease in OS in patients with PR but an increase in those with AR. Patients with either PR or AR receiving post-resistance anti-tumor treatment showed improved OS, but patients with AR had significantly longer OS than those with PR. The combination of subsequent local therapy (mOS 25.6 vs. 10.0 months) and changes in the ICI regimen (mOS 27.5 vs. 13.4 months) led to improved OS among patients with PR.
CONCLUSIONS: AR normally develops within 2 years after the beginning of treatment. Patients with AR have better characteristics in general, less invasive pattens of progression, and better prognosis compared to those with PR. Subsequent local therapy and changes in ICI treatment showed potential to overcome primary resistance.